Literature DB >> 11322500

Growth hormone-releasing hormone and growth hormone secretagogue-receptor ligands: focus on reproductive system.

E Arvat1, L Gianotti, R Giordano, F Broglio, M Maccario, F Lanfranco, G Muccioli, M Papotti, A Graziani, E Ghigo, R Deghenghi.   

Abstract

Growth hormone-releasing hormone (GHRH) and somatostatin are the most important hypothalamic neurohormones controlling growth hormone (GH) secretion. Several neurotransmitters and neuropeptides also play an important role in the control of GH secretion, mainly acting via modulation of GHRH and somatostatin. In the past two decades, particular attention has been given to a new family of substances showing a strong GH-releasing effect: GH secretagogues (GHSs). GHSs increase GH secretion in a dose- and age-related manner after iv and even oral administration. The endocrine effects of GHSs, are not fully specific for GH; they show, in fact, prolactin- (PRL), adenocorticotropic hormone- and cortisol-releasing effects. Specific GHS receptors are present in both the central nervous system and peripheral tissues, where they mediate several extraendocrine effects of GHSs. The isolation of these "orphan" receptors suggested the existence of an endogenous GHS-like ligand that could be represented by a recently discovered gastric peptide, named ghrelin. The interaction between GHSs and GHRH at the central level and in the pituitary gland, but not at peripheral level, has clearly been shown. Because GHRH and GHS receptors share the same localization in some peripheral tissues, they may have some interactions even at this level.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11322500     DOI: 10.1385/endo:14:1:035

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  114 in total

1.  Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.

Authors:  G Copinschi; R Leproult; A Van Onderbergen; A Caufriez; K Y Cole; L M Schilling; C M Mendel; I De Lepeleire; J A Bolognese; E Van Cauter
Journal:  Neuroendocrinology       Date:  1997-10       Impact factor: 4.914

Review 2.  Growth hormone-releasing peptides.

Authors:  E Ghigo; E Arvat; G Muccioli; F Camanni
Journal:  Eur J Endocrinol       Date:  1997-05       Impact factor: 6.664

3.  Immunohistochemical localization of growth hormone-releasing hormone in human gonads.

Authors:  C Moretti; A Fabbri; L Gnessi; V Bonifacio; M Bolotti; M Arizzi; Q Nazzicone; G Spera
Journal:  J Endocrinol Invest       Date:  1990-04       Impact factor: 4.256

4.  Hypothalamic stimulation of growth hormone secretion.

Authors:  L A Frohman; L L Nernardis; K J Kant
Journal:  Science       Date:  1968-11-01       Impact factor: 47.728

5.  The GH-releasing effect of Hexarelin, a synthetic hexapeptide, in newborns is lower than in young adults.

Authors:  E Bartolotta; J Bellone; G Aimaretti; E Arvat; L Benso; R Deghenghi; F Camanni; E Ghigo
Journal:  J Pediatr Endocrinol Metab       Date:  1997 Sep-Oct       Impact factor: 1.634

6.  The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.

Authors:  M Korbonits; G Kaltsas; L A Perry; P Putignano; A B Grossman; G M Besser; P J Trainer
Journal:  J Clin Endocrinol Metab       Date:  1999-07       Impact factor: 5.958

7.  Somatostatin in physiological concentrations inhibits basal and enhances luteinizing hormone-stimulated progesterone release from human granulosa-luteal cells.

Authors:  N Holst; M B Jacobsen; E Haug; T Tanbo; T Abyholm
Journal:  Hum Reprod       Date:  1995-06       Impact factor: 6.918

8.  Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty.

Authors:  J Bellone; G Aimaretti; E Bartolotta; L Benso; B P Imbimbo; V Lenhaerts; R Deghenghi; F Camanni; E Ghigo
Journal:  J Clin Endocrinol Metab       Date:  1995-04       Impact factor: 5.958

9.  Effects of dexamethasone and alprazolam, a benzodiazepine, on the stimulatory effect of hexarelin, a synthetic GHRP, on ACTH, cortisol and GH secretion in humans.

Authors:  E Arvat; B Maccagno; J Ramunni; L Di Vito; L Gianotti; F Broglio; A Benso; R Deghenghi; F Camanni; E Ghigo
Journal:  Neuroendocrinology       Date:  1998-05       Impact factor: 4.914

10.  Immunohistochemical detection of growth hormone-releasing factor in brain.

Authors:  B Bloch; P Brazeau; N Ling; P Bohlen; F Esch; W B Wehrenberg; R Benoit; F Bloom; R Guillemin
Journal:  Nature       Date:  1983 Feb 17-23       Impact factor: 49.962

View more
  4 in total

Review 1.  Ageing, growth hormone and physical performance.

Authors:  F Lanfranco; L Gianotti; R Giordano; M Pellegrino; M Maccario; E Arvat
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

2.  Ghrelin antagonized 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells.

Authors:  Juanjuan Dong; Ning Song; Junxia Xie; Hong Jiang
Journal:  J Mol Neurosci       Date:  2008-12-04       Impact factor: 3.444

3.  The traditional Japanese medicine Rikkunshito increases the plasma level of ghrelin in humans and mice.

Authors:  Tomoaki Matsumura; Makoto Arai; Yutaka Yonemitsu; Daisuke Maruoka; Takeshi Tanaka; Takuto Suzuki; Masaharu Yoshikawa; Fumio Imazeki; Osamu Yokosuka
Journal:  J Gastroenterol       Date:  2009-12-10       Impact factor: 7.527

Review 4.  Potential future options in the pharmacotherapy of female sexual dysfunction.

Authors:  Stefan Uckert; Margit E Mayer; Udo Jonas; Christian G Stief
Journal:  World J Urol       Date:  2006-12       Impact factor: 3.661

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.